Pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world's third worst-hit nation.
Also read: First COVID-19 vaccine tested in U.S. shows promising results
ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said.
In the human trials, Zydus will enroll over 1,000 subjects across multiple clinical study sites in India.
